Global medical technology company, Baxter International, has announced a quarterly cash dividend of $0.29 per share. This demonstrates their commitment ...
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.